Compare Citius Pharmaceuticals Inc (CTXR) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Honeywell International Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Honeywell International Inc trades at $234.78 (market cap $72.93B). The key difference: Honeywell International Inc is far larger — about 3644.7× Citius Pharmaceuticals Inc's market cap, and Honeywell International Inc pays a 1.22% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | HON | |
|---|---|---|
Market Cap | $20.01M | $72.93B |
Sector | Health | Industrials |
52-Week High | $1.82 | $248.79 |
52-Week Low | $0.48 | $188.14 |
Enterprise Value | $16.23M | $97.73B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Honeywell International Inc. (HON) trades at $232.35, down 4.36% amid disappointing growth guidance from a recent investor event. The stock exhibits bearish technical signals with support near $225, while fundamentals remain solid with a low P/E of 8.85 and strong profitability margins. Recent corporate actions include dividend payments and business divestitures, positioning the company as a focused automation play.
The outlook is mixed: attractive valuation and consistent earnings beats support upside toward the $320.54 consensus target, but near-term sentiment is pressured by growth concerns and technical weakness. Key risks include execution of the portfolio transformation and macroeconomic headwinds affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
